- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 10
The Center for Biosimilars® recaps the top news for the week of September 10, 2018.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 10.
Number 5: While biosimilar filgrastim and biosimilar pegfilgrastim are effective in reducing the incidence of neutropenia, adverse events were shown in a recent study to be higher in patients who receive pegfilgrastim.
Number 4: Xbrane Biopharma has announced its intention to shift its focus from generic drugs to biosimilars.
Number 3: Newly published study results show that switching to Retacrit was noninferior to continuing treatment with Epogen.
Number 2: The United Kingdom is hoping to bring more biosimilar developers’ phase 3 trials to the nation’s National Health Service.
Number 1: The FDA’s Oncologic Drugs Advisory Committee will meet next month to discuss Celltrion’s rituximab biosimilar.
Finally, last week, our e-newsletter asked whether you think that biosimilar should be approved without the need for phase 3 studies.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
